IRIS
MELILLO, ROSA MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.230
NA - Nord America 5.160
EU - Europa 4.236
SA - Sud America 736
Continente sconosciuto - Info sul continente non disponibili 260
AF - Africa 146
OC - Oceania 8
Totale 15.776
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.926
SG - Singapore 2.357
RU - Federazione Russa 1.555
IT - Italia 1.136
CN - Cina 955
VN - Vietnam 938
BR - Brasile 594
HK - Hong Kong 445
DE - Germania 300
UA - Ucraina 268
FR - Francia 191
FI - Finlandia 170
CA - Canada 148
IE - Irlanda 137
IN - India 119
NL - Olanda 113
GB - Regno Unito 110
SE - Svezia 110
BD - Bangladesh 86
JP - Giappone 73
AR - Argentina 50
MX - Messico 45
KR - Corea 39
CI - Costa d'Avorio 37
ZA - Sudafrica 37
PL - Polonia 30
IQ - Iraq 29
EC - Ecuador 26
ES - Italia 26
PH - Filippine 24
TH - Thailandia 23
ID - Indonesia 22
AT - Austria 18
CO - Colombia 18
PK - Pakistan 17
VE - Venezuela 15
TR - Turchia 14
MA - Marocco 13
CL - Cile 12
KE - Kenya 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 10
PY - Paraguay 9
TW - Taiwan 9
EG - Egitto 8
JO - Giordania 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
BE - Belgio 7
LT - Lituania 7
BG - Bulgaria 6
DZ - Algeria 6
JM - Giamaica 6
NP - Nepal 6
SA - Arabia Saudita 6
CH - Svizzera 5
CR - Costa Rica 5
PE - Perù 5
TN - Tunisia 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
HR - Croazia 4
IL - Israele 4
KZ - Kazakistan 4
NG - Nigeria 4
NI - Nicaragua 4
RO - Romania 4
SN - Senegal 4
UY - Uruguay 4
BB - Barbados 3
BY - Bielorussia 3
GE - Georgia 3
IR - Iran 3
KW - Kuwait 3
LK - Sri Lanka 3
MD - Moldavia 3
MY - Malesia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
AG - Antigua e Barbuda 2
AO - Angola 2
BH - Bahrain 2
BO - Bolivia 2
CG - Congo 2
GT - Guatemala 2
HU - Ungheria 2
IS - Islanda 2
KH - Cambogia 2
LU - Lussemburgo 2
LY - Libia 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
SO - Somalia 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
Totale 15.492
Salva come PNG Salva come JPEG
Città #
Singapore 1.039
San Jose 724
Hong Kong 429
Chandler 385
Moscow 383
Ashburn 364
Beijing 294
Jacksonville 272
Ho Chi Minh City 259
Santa Clara 227
Hanoi 204
Naples 162
Los Angeles 143
Lauterbourg 132
Princeton 132
Council Bluffs 124
Millbury 122
The Dalles 122
Nanjing 102
Boston 95
Napoli 95
Amsterdam 88
Buffalo 83
New York 79
Hefei 73
Munich 69
Dallas 65
São Paulo 61
Tokyo 61
Wilmington 56
Ann Arbor 54
Ottawa 49
Haiphong 44
Orem 44
Da Nang 40
Rome 40
Montreal 38
Nanchang 32
Redondo Beach 30
Denver 27
Chicago 26
London 26
Atlanta 25
Brooklyn 25
Tianjin 24
Warsaw 24
Chennai 23
Hebei 23
Marigliano 23
Biên Hòa 22
Kronberg 22
Milan 22
Turku 22
Des Moines 21
Poplar 21
Seattle 21
Houston 20
Boardman 18
Nuremberg 18
Rio de Janeiro 18
Frankfurt am Main 17
Johannesburg 17
Norwalk 17
Phoenix 17
Shenyang 17
Mexico City 16
Stockholm 16
Thái Nguyên 16
Falls Church 15
Salerno 15
Helsinki 14
Krefeld 14
Porto Alegre 14
Toronto 14
Woodbridge 14
Augusta 13
Cagliari 13
Changsha 13
Kochi 13
San Francisco 13
Belo Horizonte 12
Dong Ket 12
Guayaquil 12
Hangzhou 12
Seoul 12
Bacoli 11
Barano d'Ischia 11
Brasília 11
Manchester 11
Mumbai 11
Shanghai 11
Bangkok 10
Can Tho 10
Charlotte 10
Giugliano in Campania 10
Hải Dương 10
Pune 10
Tashkent 10
Washington 10
Bari 9
Totale 7.799
Salva come PNG Salva come JPEG
Nome #
Basi molecolari dell’effetto pro-tumorigenico dele chemochine nel cancro della tiroide. 617
The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression 199
PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. 196
Peptide per rigenerare i tessuti lesionati. 189
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity 180
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 171
Formyl Peptide Receptor 1 Suppresses Gastric Cancer Angiogenesis and Growth by Exploiting Inflammation Resolution Pathways 171
Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo. 169
Probiotic Lactobacillus rhamnosus GG (LGG) restrains the angiogenic potential of colorectal carcinoma cells by activating a proresolving program via formyl peptide receptor 1 167
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 162
Mast cells have a protumorigenic role in human thyroid cancer. 157
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 155
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. 155
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 151
Glucose Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal Stromal/Stem Cells on Breast Cancer Cell Lines 150
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 147
Role of Formyl Peptide Receptors In Gastrointestinal Healing 146
The lncRNA RMST is drastically downregulated in anaplastic thyroid carcinomas where exerts a tumor suppressor activity impairing epithelial-mesenchymal transition and stemness 144
AXL is an oncotarget in human colorectal cancer 144
Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1 143
AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer 143
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents 142
Molecular biology of the MEN2 gene 142
Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. 141
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma 139
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 139
New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution 138
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 135
Thyroid cancer and inflammation. 135
The Formyl Peptide Receptor 1 Exerts a Tumor Suppressor Role in Human Gastric Cancer by Suppressing Angiogenesis 134
The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. 134
Il Sistema Immunitario 134
Toll‐like receptor 7 mediates inflammation resolution and inhibition of angiogenesis in non‐small cell lung cancer 134
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 133
Inflammation in thyroid oncogenesis. 132
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. 132
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. 132
Molecular mechanisms of RET activation in human cancer 129
Helicobacter pylori Hp(2-20) promotes gastric mucosal healing and interacts with formyl-peptide receptors 128
Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth 127
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer 127
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 125
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase 123
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. 121
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 121
IL-8, But Not The Related Chemokine CXCL1, Sustains An Autocrine Circuit Necessary For the Properties and Functions of Thyroid Cancer Stem Cells. 121
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. 120
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies 120
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. 119
Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness. 118
Recent advances in understanding immune phenotypes of thyroid carcinomas: Prognostication and emerging therapies [version 1; referees: 2 approved] 118
Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. 117
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. 116
The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. 115
Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. 114
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 113
Roles of mast cells and their mediators in human thyroid carcinomas. 112
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 112
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 112
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 109
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 109
BRAF is a therapeutic target in aggressive thyroid carcinoma. 107
L’osteopontina: un nuovo marcatore biologico dei carcinomi della testa e del collo 107
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 106
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 106
Tumor Suppressor Role of Formyl Peptide Receptor 1 in Human Gastric Cancer 104
Different mutations of the RET gene cause different human tumoral diseases. 103
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. 101
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 99
The docking protein FRS2 links RET and its oncogenic forms with the RAS/MAPK cascade. 98
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 97
Functional role of the CXCR4 chemokine receptor in thyroid cancer. 96
Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. 94
INCREASED IN-VIVO PHOSPHORILATION OF RET TYROSINE 1062 IS A POTENTIAL PATHOGENETIC MECHANISM OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B. 93
The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture 93
RET\PTC activation in human thyroid carcinomas 93
ROLES OF MAST CELLS AND THEIR MEDIATORS IN HUMAN THYROID CARCINOMAS 91
Mast cells play (a) protumorigenic roles in human thyroid cancer. 91
Activation of RET oncogene and thyroid carcinogenesis 90
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes 90
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 89
Molecular mechanisms of RET activation in human neoplasia 89
Molecular mechanisms of RET activation in human cancer. 89
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. 89
Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer 88
Ret-mediated mitogenesis requires Src kinase activity. 88
Small-molecule inhibitors of chemokine receptors as novel anticancer therapy of human thyroid carcinomas. 87
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. 87
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 86
Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. 86
Tyrosines 1015 and 1062 are in vivo auto-phosphorylation site in Ret and Ret-derived oncoproteins 85
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 85
Molecular mechanisms of RET activation in human neoplasia. 85
Helicobacter pylori Hp(2-20) promotes gastric mucosal healing and interacts with formyl-peptide receptors. 85
Mast cells and basophils in angiogenesis: bridging the gap between inflammation and tumors 85
Genetics: The genomic landscape of papillary thyroid carcinoma 84
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. 83
Multiple anti-tumor effects of Reparixin on thyroid cancer 83
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 82
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 82
Totale 12.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.815
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.815
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022720 0 3 4 9 13 24 19 21 149 32 151 295
2022/20231.026 155 64 14 102 101 120 12 99 193 89 54 23
2023/2024710 27 70 95 69 44 49 30 109 13 18 128 58
2024/20253.699 221 274 17 22 63 208 389 216 296 403 1.252 338
2025/20267.236 841 500 759 756 1.245 281 763 436 888 462 159 146
2026/2027365 153 212 0 0 0 0 0 0 0 0 0 0
Totale 15.776